Cargando…
THU551 Glycoprotein-NMB (GPNMB) Is A Potential Lymphangioleiomyomatosis (LAM) Therapeutic Target And Biomarker
Disclosure: E. Gibbons: None. S.R. Hammes: None. Lymphangioleiomyomatosis (LAM) is a rare, progressive, destructive cystic lung disease affecting almost exclusively female-sexed individuals. Mutations in the tuberous sclerosis (TSC1 or TSC2) genes constitutively activate the mTORC1 pathway, promotin...
Autores principales: | Gibbons, Erin, Taya, Manisha, Wu, Huixing, McCormack, Francis X, Hammes, Stephen R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554134/ http://dx.doi.org/10.1210/jendso/bvad114.2177 |
Ejemplares similares
-
RF19 | PSUN351 Glycoprotein-NMB (GPNMB) is Pro-Tumorigenic in Lymphangioleiomyomatosis (LAM)
por: Gibbons, Erin, et al.
Publicado: (2022) -
SAT-141 Glycoprotein NMB (GPNMB) Is Pro-Tumorigenic in TSC2-Null Cancer Cells and Is a Potential Drug Target and Biomarker for Lymphangioleiomyomatosis (LAM)
por: Gibbons, Erin, et al.
Publicado: (2020) -
OR34-5 Infiltrating Neutrophils and Neutrophil Elastase (NE) Promote Tumor Growth in a Mouse Model for Lymphangioleiomyomatosis (LAM)
por: Taya, Manisha, et al.
Publicado: (2019) -
Estradiol Augments the Production and Actions of Polymorphonuclear Cells to Promote Lymphangioleiomyomatosis (LAM) Progression
por: Minor, Briaunna M N, et al.
Publicado: (2021) -
Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
por: Aichholzer, Freyja, et al.
Publicado: (2021)